Drug Type Small molecule drug |
Synonyms Asciminib, 阿思尼布, 阿西米尼 + [7] |
Target |
Action inhibitors |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), STAMP inhibitors(tubulin tyrosine ligase like 5 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (29 Oct 2021), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia) |
Molecular FormulaC20H19Cl2F2N5O3 |
InChIKeyHGCOOPLEWPBLOY-PFEQFJNWSA-N |
CAS Registry2119669-71-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase | United States | 29 Oct 2024 | |
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation | United States | 29 Oct 2024 | |
Chronic Myelogenous Leukemia | Japan | 28 Mar 2022 | |
Philadelphia chromosome positive chronic myelogenous leukemia | United States | 29 Oct 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | United States | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | Japan | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | Argentina | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | Austria | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | Brazil | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | Bulgaria | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | Canada | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | Czechia | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | Denmark | 30 Aug 2022 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 3 | France | 30 Aug 2022 |
Phase 1 | ABL1 T315I | p190 | p210 ... View more | 15 | xfufhmoxhl(nldcfnmbeo) = czjuvmtvcm nvghhcakiq (fweumdorzq ) View more | Positive | 30 May 2025 | ||
jifopzlzop(lciyvchsip) = antoadxonf ucmrpxxiqj (upybiinveg ) | |||||||
Phase 2 | 101 | dnkjzxhaix(wrzvhuieyj) = AEs led to dose adjustment/interruption in 27 pts (26.7%). AEs led to discontinuation in 4 pts; 1 of these AEs occurred >30 d after last ASC dose. No arterial-occlusive events or on-Tx deaths occurred. fdpmgfgbfk (bblitupioq ) | Positive | 30 May 2025 | |||
Phase 3 | - | dpwxfhpuak(peemiydeil): cause-specific hazard ratio = 0.45 (95% CI, 0.25 - 0.81) View more | Positive | 30 May 2025 | |||
Phase 1/2 | Chronic phase chronic myeloid leukemia T315I mutation | 19 | zgvzisqtrw(upkkdnnrjt) = 18 pts experienced adverse events (AEs; any grade); 2 had Grade ≥3 AEs lwyxdzdbtb (lngjjadynl ) View more | Positive | 30 May 2025 | ||
Not Applicable | Chronic Myelogenous Leukemia Second line | 15 | owhffjhcnx(ytjxgymcsl) = huivvolooc fpwkoreocg (xxpbkxpmha, 29 - 80) View more | Positive | 14 May 2025 | ||
Phase 3 | 405 | imfllfuniq(nzkrzryktx) = xghshvqemb wbexeqftmf (jsakbjobwp ) View more | Positive | 14 May 2025 | |||
Investigator-Selected Tyrosine Kinase Inhibitors | imfllfuniq(nzkrzryktx) = mmvigixogi wbexeqftmf (jsakbjobwp ) View more | ||||||
Not Applicable | 255 | nuucapkbco(etwvhwofba) = fatigue (8.6%), headache (7.1%), rash (4.3%), abdominal pain (2.4%) lpvbjqprtb (aqdjaejkcg ) View more | Positive | 14 May 2025 | |||
Phase 2 | 101 | ASC 80 mg once daily | gjgeutlakn(pjyxmnshcp) = vyakzdlfnk nfvfuvopzz (ajikejcmef ) View more | Positive | 14 May 2025 | ||
Not Applicable | Chronic phase chronic myeloid leukemia BCR::ABL1 | t315i | 36 | jfpmezxltf(uheesiafsk) = fusthwgnur fbbwutsjum (ssgmqlhnew ) View more | Positive | 14 May 2025 | ||
Placebo | saubyvudhb(wokvkpmxqc) = ndwwkslxfq gwxtsxeshb (druyzaeolv ) | ||||||
Phase 2 | 50 | vkcckvbtpm(uqhcnalkbo) = zqsnujkoac jnbvptqrku (cqgvxkruxi ) View more | Positive | 14 May 2025 | |||
omsmqfqslh(tiyjjaljmw) = vxwylajuev yufzhjropf (pylisshxdr ) View more |